We provide you with 20 years of free, institutional-grade data for XNCR stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of XNCR. Explore the full financial landscape of XNCR stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Feigal Ellen | Sale | -2,993 | $9.22 | $27,595 | 2025-06-16 |
| Feigal Ellen | Grant, award...etc | 13,686 | 2025-06-16 | ||
| SIMPSON TODD E | Grant, award...etc | 13,686 | 2025-06-16 | ||
| RANIERI RICHARD J | Sale | -2,993 | $9.22 | $27,595 | 2025-06-16 |
| RANIERI RICHARD J | Grant, award...etc | 13,686 | 2025-06-16 | ||
| GORMAN KEVIN CHARLES | Sale | -3,173 | $9.22 | $29,255 | 2025-06-16 |
| GORMAN KEVIN CHARLES | Grant, award...etc | 13,686 | 2025-06-16 | ||
| Klencke Barbara | Grant, award...etc | 13,686 | 2025-06-16 | ||
| Montgomery Alan Bruce | Sale | -2,215 | $9.22 | $20,422 | 2025-06-16 |
| Montgomery Alan Bruce | Grant, award...etc | 13,686 | 2025-06-16 | ||
| GUSTAFSON KURT A | Sale | -2,993 | $9.22 | $27,595 | 2025-06-16 |
| GUSTAFSON KURT A | Grant, award...etc | 13,686 | 2025-06-16 | ||
| Valente Nancy | Sale | -4,616 | $11.03 | $50,914 | 2025-05-06 |
| Cornelissen Bart Jan | Sale | -3,750 | $8.06 | $30,233 | 2025-04-14 |
| Desjarlais John R | Sale | -9,697 | $13.6 | $131,851 | 2025-03-11 |
| Valente Nancy | Sale | -2,565 | $13.6 | $34,877 | 2025-03-11 |
| Eckert Celia | Sale | -5,740 | $13.6 | $78,047 | 2025-03-11 |
| Dahiyat Bassil I | Sale | -19,716 | $13.6 | $268,080 | 2025-03-11 |
| Eckert Celia | Grant, award...etc | 21,949 | 2025-03-05 | ||
| Desjarlais John R | Grant, award...etc | 29,851 | 2025-03-05 | ||
| Cornelissen Bart Jan | Grant, award...etc | 21,949 | 2025-03-05 | ||
| Dahiyat Bassil I | Grant, award...etc | 109,745 | 2025-03-05 | ||
| Dahiyat Bassil I | Derivatives Exercise | 8,808 | 2025-02-03 | ||
| Desjarlais John R | Derivatives Exercise | 3,542 | 2025-02-03 | ||
| Montgomery Alan Bruce | Sale | -14,722 | $27.03 | $397,934 | 2024-12-04 |
| Montgomery Alan Bruce | Derivatives Exercise | 14,722 | 2024-12-04 | ||
| Dahiyat Bassil I | Sale | -49,278 | $24.07 | $1,186,363 | 2024-11-25 |
| Dahiyat Bassil I | Derivatives Exercise | 62,826 | 2024-11-25 | ||
| Dahiyat Bassil I | Sale | -3,366 | $24.02 | $80,842 | 2024-11-14 |
| Dahiyat Bassil I | Derivatives Exercise | 3,366 | 2024-11-14 | ||
| Desjarlais John R | Sale | -68,684 | $23.48 | $1,612,639 | 2024-11-13 |
| Desjarlais John R | Derivatives Exercise | 81,458 | 2024-11-13 | ||
| GORMAN KEVIN CHARLES | Sale | -2,654 | $20.68 | $54,885 | 2024-10-01 |
| GUSTAFSON KURT A | Sale | -2,503 | $20.68 | $51,762 | 2024-10-01 |
| Montgomery Alan Bruce | Sale | -1,853 | $20.68 | $38,320 | 2024-10-01 |
| Feigal Ellen | Sale | -2,503 | $20.68 | $51,762 | 2024-10-01 |
| ROSA-BJORKESON DAGMAR | Sale | -2,503 | $20.68 | $51,762 | 2024-10-01 |
| RANIERI RICHARD J | Sale | -2,503 | $20.68 | $51,762 | 2024-10-01 |
| Desjarlais John R | Sale | -36,329 | $18.32 | $665,511 | 2024-07-11 |
| Desjarlais John R | Derivatives Exercise | 50,000 | 2024-07-11 | ||
| Montgomery Alan Bruce | Grant, award...etc | 5,986 | 2024-06-17 | ||
| RANIERI RICHARD J | Grant, award...etc | 5,986 | 2024-06-17 | ||
| GUSTAFSON KURT A | Grant, award...etc | 5,986 | 2024-06-17 | ||
| Klencke Barbara | Grant, award...etc | 5,986 | 2024-06-17 | ||
| ROSA-BJORKESON DAGMAR | Grant, award...etc | 5,986 | 2024-06-17 | ||
| Feigal Ellen | Grant, award...etc | 5,986 | 2024-06-17 | ||
| GORMAN KEVIN CHARLES | Grant, award...etc | 5,986 | 2024-06-17 | ||
| Valente Nancy | Sale | -4,745 | $23.58 | $111,872 | 2024-05-03 |
| Cornelissen Bart Jan | Grant, award...etc | 42,265 | 2024-04-11 | ||
| Desjarlais John R | Sale | -1,280 | $23.5 | $30,082 | 2024-03-12 |
| Eckert Celia | Sale | -850 | $23.5 | $19,977 | 2024-03-12 |
| Dahiyat Bassil I | Sale | -2,741 | $23.5 | $64,418 | 2024-03-12 |
| Kuch John J | Sale | -849 | $23.5 | $19,953 | 2024-03-12 |
| Valente Nancy | Grant, award...etc | 19,634 | 2024-03-07 | ||
| Kuch John J | Sale | -4,474 | $23.43 | $104,821 | 2024-03-07 |
| GUSTAFSON KURT A | Sale | -14,000 | $23.18 | $324,453 | 2024-03-07 |
| GUSTAFSON KURT A | Derivatives Exercise | 15,000 | 2024-03-07 | ||
| Desjarlais John R | Grant, award...etc | 20,724 | 2024-03-07 | ||
| Desjarlais John R | Sale | -6,629 | $23.43 | $155,311 | 2024-03-07 |
| Dahiyat Bassil I | Grant, award...etc | 54,538 | 2024-03-07 | ||
| Dahiyat Bassil I | Sale | -12,528 | $23.43 | $293,519 | 2024-03-07 |
| Eckert Celia | Grant, award...etc | 13,089 | 2024-03-07 | ||
| Eckert Celia | Sale | -3,892 | $23.43 | $91,186 | 2024-03-07 |
| Desjarlais John R | Derivatives Exercise | 11,943 | 2024-02-16 | ||
| GORMAN KEVIN CHARLES | Open Market Purchase | 53 | $19.12 | 2024-02-15 | |
| Desjarlais John R | Sale | -54,108 | $19.38 | $1,048,743 | 2024-02-14 |
| Desjarlais John R | Derivatives Exercise | 68,057 | 2024-02-14 | ||
| Dahiyat Bassil I | Sale | -45,000 | $20.93 | $941,670 | 2023-12-29 |
| Dahiyat Bassil I | Derivatives Exercise | 65,001 | 2023-12-29 | ||
| GUSTAFSON KURT A | Grant, award...etc | 5,007 | 2023-06-22 | ||
| GORMAN KEVIN CHARLES | Grant, award...etc | 5,007 | 2023-06-22 | ||
| Feigal Ellen | Grant, award...etc | 5,007 | 2023-06-22 | ||
| ROSA-BJORKESON DAGMAR | Grant, award...etc | 5,007 | 2023-06-22 | ||
| Dahiyat Bassil I | Sale | -33,497 | $26.19 | $877,286 | 2023-06-22 |
| Dahiyat Bassil I | Derivatives Exercise | 76,012 | 2023-06-22 | ||
| Montgomery Alan Bruce | Grant, award...etc | 5,007 | 2023-06-22 | ||
| RANIERI RICHARD J | Grant, award...etc | 5,007 | 2023-06-22 | ||
| RANIERI RICHARD J | Grant, award...etc | 5,007 | 2023-06-21 | ||
| Valente Nancy | Grant, award...etc | 39,296 | 2023-05-03 | ||
| Yang Allen | Sale | -1,094 | $29.88 | $32,688 | 2023-03-13 |
| Eckert Celia | Sale | -711 | $29.88 | $21,244 | 2023-03-13 |
| Kuch John J | Sale | -711 | $29.88 | $21,244 | 2023-03-13 |
| Desjarlais John R | Sale | -1,230 | $29.88 | $36,752 | 2023-03-13 |
| Dahiyat Bassil I | Sale | -2,602 | $29.88 | $77,746 | 2023-03-13 |
| Kuch John J | Sale | -2,774 | $31.42 | $87,148 | 2023-03-08 |
| Eckert Celia | Sale | -2,462 | $31.42 | $77,346 | 2023-03-08 |
The information provided in this report about XNCR stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Xencor, Inc(NASDAQ:XNCR) 
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases in the United states and internationally. The company's product candidates include Obex...
Website: http://www.xencor.com
Founded: 1997
Full Time Employees: 166
Sector: Healthcare
Industry: Biotechnology